PMID- 27265450
OWN - NLM
STAT- MEDLINE
DCOM- 20171102
LR  - 20171204
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 34
IP  - 33
DP  - 2016 Jul 19
TI  - Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese 
      elderly is well tolerated and elicits immune responses.
PG  - 3875-81
LID - S0264-410X(16)30378-4 [pii]
LID - 10.1016/j.vaccine.2016.05.052 [doi]
AB  - BACKGROUND: Following primary vaccination of adults ⩾65years of age with 
      23-valent pneumococcal polysaccharide vaccine (PPSV23), immune responses increase 
      and thereafter appear to decrease over time. With increased life expectancy 
      worldwide, revaccination with PPSV23 may be required for continued protection of 
      the elderly population against pneumococcal disease. The present study evaluated 
      the immunogenicity and safety of revaccination with PPSV23 in the Japanese 
      elderly. METHODS: Depending on prior history of PPSV23 vaccination, adults aged 
      ⩾70years were given a first dose (primary group; N=81) or second dose 
      (revaccination group; N=161, at least 5years after first dose) of PPSV23 
      intramuscularly. Subjects were matched for gender, age, and number and type of 
      comorbidity across both groups. Blood samples were collected before and 4weeks 
      postvaccination to measure serotype-specific immunoglobulin G (IgG) 
      concentrations and opsonophagocytic killing activity (OPA) antibody titers to 
      serotypes included in the vaccine. Injection-site and systemic adverse events 
      (AEs) were collected for 14days postvaccination. RESULTS: Baseline 
      serotype-specific IgG geometric mean concentrations (GMCs) and OPA geometric mean 
      titers (GMTs) were generally higher in subjects with a prior history of PPSV23 
      vaccination than in PPSV23-naive subjects. The levels of IgG GMCs and OPA GMTs 
      after revaccination were generally comparable to those observed after primary 
      vaccination. Incidences of systemic AEs were comparable between the 2 groups. 
      Although incidences of injection-site AEs were higher following revaccination 
      than primary vaccination, the difference was not clinically significant as most 
      AEs were mild to moderate in intensity and resolved within 5days after 
      revaccination without treatment. CONCLUSION: Revaccination with PPSV23 was well 
      tolerated and associated with increases in serotype-specific IgG concentrations 
      and OPA titers in the elderly who received a prior PPSV23 dose at least 5years 
      before. Revaccination with PPSV23 can be safely implemented in the elderly for 
      continued prevention against pneumococcal disease. CLINICAL TRIAL REGISTRY 
      NUMBER: NCT02260882.
CI  - Copyright (c) 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Kawakami, Kenji
AU  - Kawakami K
AD  - Department of Respiratory Medicine, National Hospital Organization Nagasaki 
      Kawatana Medical Center, Kawatana, Nagasaki, Japan.
FAU - Kishino, Hiroyuki
AU  - Kishino H
AD  - Japan Development, MSD K.K., Tokyo, Japan. Electronic address: 
      hiroyuki.kishino@merck.com.
FAU - Kanazu, Shinichi
AU  - Kanazu S
AD  - Japan Development, MSD K.K., Tokyo, Japan.
FAU - Toshimizu, Nobuhito
AU  - Toshimizu N
AD  - Japan Development, MSD K.K., Tokyo, Japan.
FAU - Takahashi, Kenichi
AU  - Takahashi K
AD  - Japan Development, MSD K.K., Tokyo, Japan.
FAU - Sterling, Tina
AU  - Sterling T
AD  - MRL, Merck Sharp & Dohme Corp., Kenilworth, NJ, USA.
FAU - Wang, Meihua
AU  - Wang M
AD  - MRL, Merck Sharp & Dohme Corp., Kenilworth, NJ, USA.
FAU - Musey, Luwy
AU  - Musey L
AD  - MRL, Merck Sharp & Dohme Corp., Kenilworth, NJ, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02260882
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20160610
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (23-valent pneumococcal capsular polysaccharide vaccine)
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Pneumococcal Vaccines)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Bacterial/blood
MH  - Female
MH  - Humans
MH  - *Immunization, Secondary
MH  - Immunogenicity, Vaccine
MH  - Immunoglobulin G/blood
MH  - Japan
MH  - Male
MH  - Pneumococcal Infections/*prevention & control
MH  - Pneumococcal Vaccines/*therapeutic use
OTO - NOTNLM
OT  - 23-valent pneumococcal polysaccharide vaccine
OT  - Immunoglobulin G
OT  - Japanese elderly
OT  - Opsonophagocytic killing activity
OT  - Pneumococcal disease
OT  - Revaccination
EDAT- 2016/06/07 06:00
MHDA- 2017/11/03 06:00
CRDT- 2016/06/07 06:00
PHST- 2016/01/29 00:00 [received]
PHST- 2016/04/21 00:00 [revised]
PHST- 2016/05/18 00:00 [accepted]
PHST- 2016/06/07 06:00 [entrez]
PHST- 2016/06/07 06:00 [pubmed]
PHST- 2017/11/03 06:00 [medline]
AID - S0264-410X(16)30378-4 [pii]
AID - 10.1016/j.vaccine.2016.05.052 [doi]
PST - ppublish
SO  - Vaccine. 2016 Jul 19;34(33):3875-81. doi: 10.1016/j.vaccine.2016.05.052. Epub 
      2016 Jun 10.